



RAMAROSON ANDRIANTSITOHAINA, PharmD, PhD
(Montpellier, France)

Institution INSERM U1046 - UMR CNRS 9214 - University Montpellier

Short CV

Doctor of Pharmacy (PharmD), University Strasbourg (France);
PhD in Molecular and Cellular Pharmacology, University Strasbourg (France)
Director of Research “1st Classe” INSERM

Institutional Responsibilities

Former Director of INSERM UNIT U1063 (2011-2021)
Member of the Specialized Scientific Committee n°3 of the INSERM/
Former Director of Research Federative Structure ICAT 4208/ University of Angers
Commissions of trust: members of 6 international evaluation committees or advisory board

Research interests: Extracellular vesicles, metabolic diseases, polyphenols

Track record: 238 publications in PubMed (H index 57; number of citations 14,488)

Supervision: 12 Postdoctoral students from 5 countries/ 36 PhD students from 10 countries / 50 Master students from 10 countries

Grants: PI of national and international grants total amount of funding the last five years: 1.8 million €
Since 2005, R Andriantsitohaina (DR1 INSERM 238 publications, H index 57) leads a research team involved in the isolation, characterization and bioactions of EVs from different cohort (sepsis, Crohn, obstructive sleep apnea, preeclampsia, metabolic syndrome, obesity, diabetes). He is internationally recognized in the field of EVs and cardiovascular diseases. Demonstration of a correlation between the increase of total circulating EVs with some EV subsets, endothelial dysfunction, vascular hyporeactivity and in the development of atherosclerosis. EVs as potential biomarkers and biological vectors of obstructive sleep apnea associated vascular impairment by promoting endothelial dysfunction and modifying its secretome, inflammation and vascular hyperreactivity. EVs bearing sonic hedgehog as a novel therapeutic approach in heart ischemia/reperfusion. sEVs can be used for the selective delivery of therapeutic agents from the blood to the brain to target neurons in the ventromedial of hypothalamus, extending this exciting nanobiomedecine approach to potential applications for the treatment of obesity.

9th European Section Meeting of the
International Academy of Cardiovascular Sciences

October 4 - 7, 2023 TIMIȘOARA, ROMANIA